Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial

NCT04498767 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT04498767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04498767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Not applicable
Overall status
Recruiting
Start date
June 10, 2021
Completion date
February 1, 2030
Enrollment
200 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, colon cancer, esophageal cancer, gastric cancer, gynecologic cancer, head and neck cancer, hepatobiliary cancer, melanoma, oligometastasis, pancreatic cancer, renal cancer, sarcoma, skin cancer, small bowel cancer, upper urinary tract carcinoma